Provided by Tiger Trade Technology Pte. Ltd.

CEL-SCI Corp

5.00
+0.10002.04%
Post-market: 5.000.00000.00%17:17 EST
Volume:40.43K
Turnover:204.22K
Market Cap:42.04M
PE:-0.80
High:5.23
Open:4.88
Low:4.88
Close:4.90
52wk High:20.41
52wk Low:1.98
Shares:8.41M
Float Shares:6.64M
Volume Ratio:0.54
T/O Rate:0.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.2655
EPS(LYR):-6.2655
ROE:-176.32%
ROA:-56.23%
PB:2.63
PE(LYR):-0.80

Loading ...

Press Release: ITAÚ UNIBANCO - Material Fact: Guidance 2026

Dow Jones
·
Feb 05

Geert R. Kersten, CEO, Reports Acquisition of CEL-SCI Corporation Common Shares

Reuters
·
Jan 26

Press Release: CEL-SCI Reports Fiscal 2025 Results

Dow Jones
·
Dec 29, 2025

CEL-SCI posts FY net operating loss of USD 24.8 million

Reuters
·
Dec 29, 2025

CEL-SCI CEO Geert R. Kersten Reports Acquisition of Common Shares

Reuters
·
Dec 05, 2025

Financial Morning Brief: PBOC Releases Latest Data! October Social Financing Stock Up 8.5% YoY, China Makes Breakthrough in 6G Technology | November 14, 2025

Deep News
·
Nov 14, 2025

Key Financial News Highlights for November 14, 2025

Deep News
·
Nov 14, 2025

CEL-SCI files to sell 375,000 shares of common stock for holders

TIPRANKS
·
Nov 08, 2025

Trident CTO to Share Customer Impact Insights at Tencent Cloud Day Singapore 2025

GlobeNewswire
·
Nov 06, 2025

Press Release: GERDAU S.A. - CONSOLIDATED INFORMATION

Dow Jones
·
Oct 31, 2025

CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference

Reuters
·
Oct 20, 2025

Half-Yearly Results

GlobeNewswire
·
Oct 14, 2025

CELSCI Corporation to Present at LD Micro Main Event Investor Conference

Reuters
·
Oct 10, 2025

Positive Buy Rating for Palvella Therapeutics Driven by Promising CVM Treatment and Market Potential

TIPRANKS
·
Oct 09, 2025

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

GlobeNewswire
·
Sep 28, 2025

Sheyang County Accelerates High-Quality Development Through Multi-Dimensional Growth Strategy

Deep News
·
Sep 18, 2025

First Berlin Equity Research Reiterates BUY Rating for CEL-SCI Corporation, Sets Price Target at USD 60

Reuters
·
Sep 01, 2025

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

GlobeNewswire
·
Aug 30, 2025

CEL-SCI Corporation Completes $10 Million Public Offering to Advance Cancer Immunotherapy Development

Reuters
·
Aug 30, 2025

CEL-SCI Corp Shares Plunge Over 30% Following $10 Million Public Offering Pricing Announcement

Deep News
·
Aug 28, 2025